廣告
香港股市 已收市
  • 恒指

    17,716.47
    -373.46 (-2.06%)
     
  • 國指

    6,324.05
    -153.19 (-2.37%)
     
  • 上證綜指

    2,945.85
    -26.67 (-0.90%)
     
  • 道指

    39,177.99
    +50.19 (+0.13%)
     
  • 標普 500

    5,483.70
    +5.80 (+0.11%)
     
  • 納指

    17,856.28
    +51.12 (+0.29%)
     
  • Vix指數

    12.48
    -0.07 (-0.56%)
     
  • 富時100

    8,211.59
    -13.74 (-0.17%)
     
  • 紐約期油

    81.68
    +0.78 (+0.96%)
     
  • 金價

    2,337.60
    +24.40 (+1.05%)
     
  • 美元

    7.8087
    -0.0003 (-0.00%)
     
  • 人民幣

    0.9301
    +0.0001 (+0.01%)
     
  • 日圓

    0.0484
    +0.0001 (+0.17%)
     
  • 歐元

    8.3670
    +0.0287 (+0.34%)
     
  • Bitcoin

    62,286.09
    +394.52 (+0.64%)
     
  • CMC Crypto 200

    1,293.69
    +27.55 (+2.18%)
     

Obesity-Drug Developers Look at What’s Next for a $100 Billion Market

Obesity-Drug Developers Look at What’s Next for a $100 Billion Market

Oppenheimer analyst Jay Olson spent several days last week listening as companies such as Eli Lilly discussed how to improve on blockbusters like Zepbound and Novo Nordisk’s Wegovy.